Tag Archives: AZILECT

Business, Finance, Occupation & Industry

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neuro

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Teva to Present New Research on CNS Product Portfolio and Pipeline at 2013 American Academy of Neurology Annual Meeting

LATE-BREAKING ORAL PRESENTATION PLANNED FOR AZILECT ® (RASAGILINE TABLETS)

JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYS: TEVA) today announced that 15 abstracts highlighting study results for Parkinson’s disease (PD) and relapsing-remitting multiple sclerosis (RRMS) will be presented during the 65th American Academy of Neurology (AAN) annual meeting in San Diego, Calif., March 16-23, 2013. New data for AZILECT® (rasagiline tablets), an MAO-B inhibitor for the treatment of PD, will be presented as part of the meeting’s Emerging Science program (formerly known as Late-Breaking Science) on Wednesday, March 20th at 5:45pm PST.

“We are pleased with the variety of topics and quality of research results that will be presented at AAN this year,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “Teva’s legacy in CNS is grounded in our commitment to ongoing collaboration with academia, medical institutions, and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases, such as RRMS and Parkinson’s disease.”

Featured presentations include:

  • Results from a Phase IV clinical study evaluating AZILECT® as Add on to Dopamine Agonists in the Treatment of Parkinson’s disease (ANDANTE).
  • Findings from the first year of follow-up in the Therapy Optimization in Multiple Sclerosis (TOP MS) study, the largest prospective Phase IV study conducted in RRMS, providing insight into the impact of adherence to therapy, as well as data demonstrating that more patients on COPAXONE® (glatiramer acetate) persisted with treatment than those on beta interferon (IFN).
  • Results from the Phase III ALLEGRO study in RRMS at 36 months, comparing the progression of disability and safety of patients treated with laquinimod for three years (Early-Start) and in patients originally treated with placebo in the double-blind (DB) phase and switched to laquinimod treatment (Delayed-Start) in the open-label (OL) phase of the ALLEGRO trial.

Platform Presentation/Poster Session Details:


AZILECT
 ®